{
  "id": 17126219,
  "title": "Illumina shares tumble 12% despite earnings beat on China woes",
  "url": "https://urgent.news/2026/10/29/illumina-shares-tumble-12-despite-earnings-beat-on-china-woes",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-29T21:29:10.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/earnings/illumina-shares-tumble-12-despite-earnings-beat-on-china-woes-4985348"
  },
  "original_language": "en",
  "account": null,
  "summary": "Illumina Inc (NASDAQ:ILMN) experienced a 12% drop in shares after-hours following the release of its third-quarter earnings, despite the company exceeding analyst expectations. The genomics company reported adjusted earnings per share of $1.44, surpassing the consensus of $1.36, while revenue reached $1.17 billion, excluding tariff refunds, surpassing the $1.15 billion estimate. However, China revenue declined by 0.1% during the quarter, casting a shadow over the overall positive performance. Illumina has raised its full-year 2026 guidance, projecting revenue between $4.64 billion and $4.66 billion, surpassing the prior guidance of $4.60 billion to $4.64 billion. CEO Jacob Thaysen attributed the strong performance to healthy clinical demand and robust NovaSeq X placements, stating that the company is raising its full-year revenue and earnings guidance based on continued momentum.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}